OnabotulinumtoxinA OBT-A

PreclinicalSmall molecule

FFondazione Policlinico Universitario Campus Bio-Medico

OnabotulinumtoxinA OBT-A is one of 40 small molecule programs targeting Migraine. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MigraineActive, not recruiting

MigrainePreclinical

Active, not recruiting

Competition

Competitive Landscape

102 competitors in Migraine

#DrugCompanyPhaseTrials

Zonegran

AAzurity Pharmaceuticals

Phase 3

3 2

Effient

CCosette Pharmaceuticals, Inc.

Phase 3

1 3

Magnesium

SSpherium Biomed

Phase 3

3 4

Triptans

Pfizer

Phase 3

2 5

Aspirin /d

TThe First Affiliated Hospital with Nanjing Medical University

Phase 3

1 6

Flunarizine

AAspartes Pharmaceuticals, Inc.

Phase 3

9 7

BAT7104

Teva

Phase 3

1 8

Tizanidine Hydrochloride

EElan Pharmaceuticals

Phase 3

1 9

Bayer Aspirin

Bayer

Preclinical

2 10

Cervidil

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Migraine1 trial

OnaBotulinumtoxin-A in Chronic Migraine Patients with Short or Long Disease History (the BACH Study)

Recruiting·FFondazione Policlinico Universitario Campus Bio-Medico··NCT06537700·115 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OnabotulinumtoxinA OBT-A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OnabotulinumtoxinA OBT-A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OnabotulinumtoxinA OBT-A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fondazione Policlinico Universitario Campus Bio-Medico company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFondazione Policlinico Universitario Campus Bio-Medico

OnabotulinumtoxinA OBT-A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Migraine1 trial

References

Drug Info

Quick Facts

Related News